Analysts expect Fulcrum Therapeutics to report zero revenue and a consensus net loss of $0.10 per share, with the current stock price of $3.77 trading well below the $8.20 average analyst target.
Investors are primarily focused on the company’s liquidity and updates regarding the pending all-stock merger with Slate Medicines following the discontinuation of its lead clinical assets.
The company recently halted its sickle cell program, pociredir, due to FDA safety concerns and implemented a massive workforce reduction to extend its cash runway into 2029. This strategic shift follows the failure of the Phase 3 REACH trial, making the Slate transaction the critical path for future operations.